Simvastatin inhibits cysteine‐rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin‐1/FoxO3a signaling
- 12 December 2012
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (3) , 639-649
Abstract
Objective: To examine the role of sirtuin‐1 (SIRT‐1)/FoxO3a in the expression of cysteine‐rich protein 61 (CYR‐61) in rheumatoid arthritis synovial fibroblasts (RASFs) and the influence of simvastatin on this pathway, and to determine the relationship between disease progression and FoxO3a/CYR‐61 signaling in synovial fibroblasts in vivo using a rat model of collagen‐induced arthritis (CIA).Methods: In RASFs, the expression of CYR‐61 and SIRT‐1, the localization of FoxO3a in the nucleus/cytoplasm, and the phosphorylation/acetylation of FoxO3a were examined by Western blotting. Secretion of CCL20 was assessed by enzyme‐linked immunosorbent assay. Promoter activity of the Cyr61 gene was evaluated by luciferase assay, with or without forced expression of FoxO3a and SIRT‐1 by lentiviral transduction. FoxO3a–Cyr61 promoter interaction was examined by chromatin immunoprecipitation. In rats with CIA, the expression of CYR‐61 and phosphorylated FoxO3a in synovial fibroblasts was examined by immunohistochemistry.Results: In RASFs, simvastatin suppressed the tumor necrosis factor α (TNFα)–induced production of CYR‐61 and CCL20. Nuclear levels of FoxO3a were decreased after TNFα stimulation of RASFs, and forced expression of FoxO3a reversed the inductive effects of TNFα on CYR‐61. Simvastatin inhibited the nuclear export, phosphorylation, and acetylation of FoxO3a and maintained its binding to the Cyr61 promoter. Forced expression of SIRT‐1 in RASFs led to decreased levels of CYR‐61 and deacetylation of FoxO3a. Following treatment with simvastatin, the expression of SIRT‐1 was up‐regulated and SIRT‐1/FoxO3a binding was enhanced in RASFs. In rats with CIA, intraarticular injection of simvastatin alleviated arthritis and suppressed CYR‐61 expression and FoxO3a phosphorylation in synovial fibroblasts.Conclusion: CYR‐61 is important in the pathogenesis of RA, and SIRT‐1/FoxO3a signaling is crucial to induction of CYR‐61 in RASFs. Simvastatin plays a beneficial role in inflammatory arthritis through its up‐regulation of SIRT‐1/FoxO3a signaling in synovial fibroblasts. Continued study of the pathways linking sirtuins, FoxO proteins, and the inflammatory responses of RASFs may provide new insights into the pathophysiology of RA.Keywords
This publication has 42 references indexed in Scilit:
- Cyr61 Induces IL-6 Production by Fibroblast-like Synoviocytes Promoting Th17 Differentiation in Rheumatoid ArthritisThe Journal of Immunology, 2012
- Simvastatin inhibits cytokine‐stimulated Cyr61 expression in osteoblastic cells: A therapeutic benefit for arthritisArthritis & Rheumatism, 2011
- Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritisImmunological Reviews, 2009
- A critical role of Cyr61 in interleukin‐17–dependent proliferation of fibroblast‐like synoviocytes in rheumatoid arthritisArthritis & Rheumatism, 2009
- Foxo in the immune systemOncogene, 2008
- Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal modelJournal of Experimental Medicine, 2007
- Forkhead Transcription Factor FOXO3a Is a Negative Regulator of Angiogenic Immediate Early Gene CYR61, Leading to Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal HyperplasiaCirculation Research, 2007
- All in the CCN family: essential matricellular signaling modulators emerge from the bunkerJournal of Cell Science, 2006
- Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease‐discordant monozygotic twinsArthritis & Rheumatism, 2006
- The Angiogenic Factor Cyr61 Activates a Genetic Program for Wound Healing in Human Skin FibroblastsJournal of Biological Chemistry, 2001